相似文献
1
Potential savings from greater use of $4 generic drugs.
Arch Intern Med. 2011 Mar 14;171(5):468-9. doi: 10.1001/archinternmed.2011.46.
2
Brand-name versus generic drugs.
Health Aff (Millwood). 2011 Oct;30(10):2027-8; author's reply 2028. doi: 10.1377/hlthaff.2011.0964.
3
Needed assumptions for potential savings from greater use of $4 generic drugs.
Arch Intern Med. 2011 Sep 26;171(17):1594-5; author reply 1595-6. doi: 10.1001/archinternmed.2011.410.
4
Prescription drugs and health care reform.
Pharmacotherapy. 1993 Nov-Dec;13(6):583-9.
5
Prescription drug costs and the generic dispensing ratio.
J Manag Care Pharm. 2010 Sep;16(7):502-6. doi: 10.18553/jmcp.2010.16.7.502.
6
[More than "cheap copies". Generic drugs promote medical progress].
MMW Fortschr Med. 2004 Jun 10;146(24):51.
7
The use of generic drugs in prevention of chronic disease is far more cost-effective than thought, and may save money.
Health Aff (Millwood). 2011 Jul;30(7):1351-7. doi: 10.1377/hlthaff.2010.0431.
8
Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
J Manag Care Pharm. 2011 Mar;17(2):123-32. doi: 10.18553/jmcp.2011.17.2.123.
9
Summaries for patients. Potential savings with substitution of generic drugs for brand-name drugs.
Ann Intern Med. 2005 Jun 7;142(11):I30. doi: 10.7326/0003-4819-142-11-200506070-00002.
10
Medicaid payment for generic drugs: achieving savings and access.
Issue Brief George Wash Univ Natl Health Policy Forum. 2010 Sep 30(839):1-16.
引用本文的文献
1
COVID-19 pandemic and initiation of treatment for atrial fibrillation: a nationwide analysis of claims data.
BMC Cardiovasc Disord. 2023 Dec 8;23(1):604. doi: 10.1186/s12872-023-03614-z.
2
Empirical Assessment of the Impact of Low-Cost Generic Programs on Adherence-Based Quality Measures.
Pharmacy (Basel). 2017 Mar 8;5(1):15. doi: 10.3390/pharmacy5010015.
3
Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.
Milbank Q. 2017 Sep;95(3):554-601. doi: 10.1111/1468-0009.12279.
4
Estimation of Missed Statin Prescription Use in an Administrative Claims Dataset.
J Manag Care Spec Pharm. 2017 Sep;23(9):936-942. doi: 10.18553/jmcp.2017.23.9.936.
5
Quantification of missing prescriptions in commercial claims databases: results of a cohort study.
Pharmacoepidemiol Drug Saf. 2017 Apr;26(4):386-392. doi: 10.1002/pds.4165. Epub 2017 Jan 25.
6
Small Ideas for Saving Big Health Care Dollars.
Rand Health Q. 2014 Mar 1;4(1):4. eCollection 2014 Spring.
7
The Prevalence and Predictors of Low-Cost Generic Program Use in the Pediatric Population.
Drugs Real World Outcomes. 2015;2(4):411-419. doi: 10.1007/s40801-015-0051-4. Epub 2015 Dec 1.
8
Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults.
J Manag Care Spec Pharm. 2015 Dec;21(12):1162-70. doi: 10.18553/jmcp.2015.21.12.1162.
9
The relationship between violence in Northern Mexico and potentially avoidable hospitalizations in the USA-Mexico border region.
J Public Health (Oxf). 2016 Mar;38(1):14-23. doi: 10.1093/pubmed/fdv012. Epub 2015 Feb 19.
10
Completeness of prescription information in US commercial claims databases.
Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):899-906. doi: 10.1002/pds.3458. Epub 2013 May 21.
Zotero 插件